AM-Pharma

We're excited to share that our CEO, Juliane Bernholz, PhD, will be in San Francisco for the 43rd Annual J.P. Morgan Healthcare Conference, January 13 – 16. If you're attending and would like to learn more about how we are developing our lead asset, ilofotase alfa, for patients living with #hypophosphatasia and cardiac surgery-associated renal damage, contact us. We look forward to engaging with industry leaders and investors to provide an update on our recent clinical milestones and upcoming corporate development plans. #IlofotaseAlfa #JPM2025 #JPM25 #CSARD #HPP

AM-Pharma’s CEO, Juliane Bernholz, PhD, will participate in the Jefferies London Healthcare Conference held from November 19 to 21. Meet with Juliane to hear about our latest milestones and our clinical strategy for the development of ilofotase alfa as an enzyme replacement therapy in hypophosphatasia and preventative treatment for cardiac surgery-associated renal damage. #Jefferies

Save the date! Join our CEO, Juliane Bernholz, PhD, for her corporate presentation next week at the LSX - partnering for Life Science eXecutives Inv€$tival Showcase on Monday, November 18, at 11:00 am GMT in London. In her presentation, Juliane will discuss how we are advancing our proprietary compound, ilofotase alfa, as a potential treatment for cardiac surgery-associated renal damage and hypophosphatasia. Access the partnering platform to book a one-to-one meeting with Juliane to discuss AM-Pharma’s latest clinical updates and corporate outlook for 2025. #LSX #investival

On World #Hypophosphatasia (HPP) Day, we at AM-Pharma raise awareness and give support to people living with this rare bone disease. HPP patients have low levels of alkaline phosphatase, resulting in bone injuries, muscle weakness and severe pain. We are currently advancing our recombinant alkaline phosphatase, ilofotase alfa, through clinical evaluation as a potential enzyme replacement therapy for HPP. Find out more about our HPP program here: https://lnkd.in/dqXnYrGQ #WorldHPPDay #hypophosphatasia

We are excited for the BIO-Europe conference kick-off in Stockholm, Sweden, next week! Our CEO Juliane Bernholz, PhD, is available for one-on-one meetings with industry colleagues and investors. Make sure to catch up with Juliane to hear about AM-Pharma’s latest achievements and upcoming development plans for ilofotase alfa as a novel treatment of severe medical conditions, particularly cardiac surgery-associated renal damage and hypophosphatasia. #bioeurope #bioeurope2024

Meet our CEO, Juliane Bernholz, PhD, at the American Society of Nephrology Kidney Week 2024 in San Diego, from October 23-27. #KidneyWeek is the world's premier nephrology meeting and a platform to discuss the latest scientific and medical advances in kidney disease. On Thursday, October 24, at 4:30 pm PT, Prof. Peter Pickkers will be presenting in the session: “Emerging Therapies for AKI: Bright Horizons”, to discuss ilofotase alfa and the reno-protective effects observed in REVIVAL and our ongoing Phase 2 study in cardiac surgery-associated renal damage, a severe surgical complication that can lead to long-term impairment of kidney function. #nephrology #renaldamage

On #WorldHeartDay, we say “YES” to inspire action for heart health and raise awareness of heart conditions like cardiac-surgery-associated renal damage (CSA-RD), a critical surgical complication for which there is no pharmacological therapy. CSA-RD arises from acute kidney injury following open-heart surgery and can result in the need for renal replacement therapy such as dialysis. We are currently evaluating ilofotase alfa as a preventative treatment for CSA-RD in a Phase 2 clinical trial. Together with the World Heart Federation, we invite you to sign the petition for national heart action plans around the world: https://lnkd.in/gzNcyzwb. #UseHeart #WorldHeartDay #HeartYes #CSARD

Make sure to attend the presentations on September 26 at 3:45 pm ET and September 29 at 4:30 pm ET, by Dr. Lothar Seefried, University of Wuerzburg, on the results of our open-label Phase 1b study evaluating ilofotase alfa in adult hypophosphatasia (HPP) patients. At the American Society for Bone and Mineral Research (ASBMR) Annual Meeting in Toronto, Canada, held from September 27-30, Dr. Lothar Seefried will discuss the pronounced effect on all HPP disease-relevant biomarkers together with a positive safety and tolerability profile that ilofotase alfa achieved in adult HPP patients. Our CEO, Juliane Bernholz, PhD, is also attending the conference and is looking forward to discussing AM-Pharma’s development plan for ilofotase alfa as a new treatment for hypophosphatasia. #hypophosphatasia #HPP #ASBMR

Check out Scrip’s report on the roundtable discussion, “Preparing for First-in-Human: Overcoming Obstacles & Seizing Opportunities in Early Phase Biotech Research” that our CEO, Juliane Bernholz, PhD attended as a panelist during the Swiss Biotech Days. https://lnkd.in/exgCb6dZ #BiotechResearch #ScienceRoundtable 

Join us for engaging discussions at the Critical Care Clinical Trialists Workshop in Washington, DC, from June 13-15. Peter Pickkers, MD, PhD, Principal Investigator, will present the trial design for our ongoing Phase 2 study assessing ilofotase alfa as a preventative treatment for cardiac surgery-associated renal damage. Don’t miss his oral presentation on Thursday, June 13 during Session 2 from 10:50 am – 12 pm EDT.                                                                                                          Our Senior Director, Project Management Office, Liesbeth Hof will provide her industry perspectives to Session 5, “Positive trials in critical care: the key role of regulators” from 5:00 pm – 6:45 pm EDT on Thursday, June 13. #3ct #criticalcare #clinicalresearch